CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Oculis CEO Riad Sherif, MD, provides a status report on OCS-01, OCS-02 and OCS-05 eye drops.
OCS-01 would be the first topical treatment for diabetic macular edema if approved by the FDA, according to Sherif. OCS-02 is a TNF alpha blocker for inflammation with indications in dry eye disease and uveitis, while OCS-05 is an SGK-2 activator designed to treat acute optic neuritis.
“If this product works in acute optic neuritis, it really opens the door for multiple clinical applications for (Read more...)